Isofuranone compounds useful as hpk1 inhibitors

A compound of Formula (I):

• or a salt thereof, wherein:
• X is CH or N;
• Y is CR5 or N;
• R1 is —C(O)OH, —C(O)O(C1-3 alkyl), —C(O)NHR1a, —NHC(O)R1a, —C(O)NHNH2, —C(O)NHNHC(O)R1b, —C(O)NHNHC(═NCH2CH3(NH(CH2)2-4N(CH3)2), 1,8-dioxa-3-azaspiro[4.5]decenyl, or a cyclic group selected from oxadiazolyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, thiadiazolyl, pyrazinyl, imidazolyl, triazolyl, isoxazolyl, and dihydrooxazolyl, each substituted with zero to 2 R1c;
• R1a is C1-4 alkyl, C1-3 fluoroalkyl, C1-2 cyanoalkyl, —CH2CH2OCH3, —CH2C≡CH, —(CH2)2-3N(CH3)2, —CH(CH3)(phenyl), or —(CH2)mRa;
• Ra is C3-7 cycloalkyl, C5-8 bicycloalkyl, 4- to 7-membered heterocyclyl, 5- to 8-membered bicyclic nitrogen containing heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, each substituted with zero to 4 Rx;
• each Rx is independently selected from F, Cl, —CN, —OH, C1-3 alkyl, —CD3, —CF3, —OCH3, —CH2(morpholinyl), phenyl, and benzyl;
• m is zero, 1, 2, 3, 4, or 5;
• R1b is —C(CH3)2OH, —C(CF3)(CH3)OH, cyclopropyl, pyridinyl, or pyrazinyl;
• each R1c is independently F, C1-4 alkyl, C2-6 hydroxyalkyl, C1-4 fluoroalkyl, C2-4 hydroxy-fluoroalkyl, —(CH2)nRc, ═O, —S(C1-2 alkyl), azetidinyl, morpholinyl, piperidinyl, tetrahydropyranyl, dioxotetrahydrothiopyranyl, fluorophenyl, pyridinyl, pyridazinyl, azabicyclo[2.2.2]octanyl, fluoroazabicyclo[2.2.2]octanyl, aminobicyclo[1.1.1]pentanyl, dimethylaminobicyclo[1.1.1]pentanyl, acetamidobicyclo[1.1.1]pentanyl, (methoxycarbonyl)aminobicyclo[1.1.1]pentanyl, or C3-6 cycloalkyl substituted with zero to 2 substituents independently selected from F, —CN, —CF3, —CH2OH, and —OC(O)(difluorazetidinyl);
• Rc is 4- to 7-membered heterocyclyl or 5- to 8-membered bicyclic nitrogen containing heterocyclyl, each substituted with zero to 4 Rx;
• n is zero, 1, 2, 3, 4, or 5;
• R2 is:
• (i) C1-6 alkyl substituted with zero to 6 substituents independently selected from F, Cl, —CN, —OH, C1-3 alkoxy, C1-3 fluoroalkoxy, C3-6 cycloalkyl, and —NRyRy;
• (ii) —CHR2aR2b, —(CH2)1-3NRy(CH2)1-3NRyRy, —(CRyRy)1-2NRyC(O)OCH2(phenyl), —CHR2bCH2R2a, or —CH2CH2C(O)R2a;
• or
• (iii) a cyclic group selected from cyclopropyl, indazolyl, phenyl, piperidinyl, pyrazolyl, oxetanyl, and tetrahydropyrido[3,4-d]pyrimidinyl, each substituted with zero to 1 substituent selected from —CN, —CH3, —SCH3, pyrimidinyl, and phenyl;
• R2a is C3-6 cycloalkyl, oxadiazolyl, oxazolyl, oxetanyl, phenyl, pyrazolyl, pyrazolo[1,5-a]pyridinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, tetrahydropyrido[3,4-d]pyrimidinyl, or thiazolyl, each substituted with zero to 2 R2c;
• R2b is H, —OH, C1-3 alkyl, C-2 fluoroalkyl, C1-3 hydroxyalkyl, —CH2OCH3, —CH2OCF3, —CH2NRyRy, —CH2S(C1-2 alkyl), or —CH2N3;
• each R2c is independently F, Cl, —CN, —OH, C-2 alkyl, C1-3 hydroxyalkyl, C-2 aminoalkyl, C-2 alkoxy, C1-2 fluoroalkoxy, —CH2O(C1-2 alkyl), —NRyC(O)(C1-2 alkyl), —S(C1-2 alkyl), —S(O)2(C1-4 alkyl), phenyl, methyloxiranyl, or pyrimidinyl;
• each Ry is independently H or —CH3;
• R3 is H or —CH3;
• R4 is H or —CH3;
• or R3 and R4 together with the carbon atom to which they are attached form a C4-6 cycloalkyl ring;
• and
• each R5 is independently H or halo.